151 related articles for article (PubMed ID: 38605875)
1. Medical cost of breast cancer services in Serbia between 2010 and 2019: national data report.
Rancic N; Todorovic M; Stepovic M; Vekic S; Kostic D; Ratkovic M; Radevic S; Simic R; Dragojevic Simic V
Front Public Health; 2024; 12():1378886. PubMed ID: 38605875
[No Abstract] [Full Text] [Related]
2. Pharmacoeconomic Aspects of Low Back Pain Treatment: Cost of Illness Study in the Republic of Serbia.
Radoičić MJ; Božović BV; Ilić KD; Janković SM; Anđelković JZ; Kostić MJ
Acta Med Port; 2019 Apr; 32(4):272-278. PubMed ID: 31067421
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of breast cancer in northern Serbia.
Milovic M; Tamas T; Crnobrnja V; Paut Kusturica M
Front Public Health; 2023; 11():1265301. PubMed ID: 38162600
[TBL] [Abstract][Full Text] [Related]
4. Comparison of male and female breast cancer incidence and mortality trends in Central Serbia.
Sipetic-Grujicic S; Murtezani Z; Ratkov I; Grgurevic A; Marinkovic J; Bjekic M; Miljus D
Asian Pac J Cancer Prev; 2013; 14(10):5681-5. PubMed ID: 24289562
[TBL] [Abstract][Full Text] [Related]
5. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
[TBL] [Abstract][Full Text] [Related]
6. Reimbursement of targeted cancer therapies within 3 different European health care systems.
Mihajlović J; Dolk C; Tolley K; Simoens S; Postma MJ
Clin Ther; 2015 Feb; 37(2):474-80. PubMed ID: 25638534
[TBL] [Abstract][Full Text] [Related]
7. [Assessment of diabetes mellitus type 2 treatment costs in the Republic of Serbia].
Biorac N; Jakovljević M; Stefanović D; Perović S; Janković S
Vojnosanit Pregl; 2009 Apr; 66(4):271-6. PubMed ID: 19432292
[TBL] [Abstract][Full Text] [Related]
8. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
9. Radiation therapy remains the key cost driver of oncology inpatient treatment.
Jakovljevic M; Zugic A; Rankovic A; Dagovic A
J Med Econ; 2015 Jan; 18(1):29-36. PubMed ID: 25268728
[TBL] [Abstract][Full Text] [Related]
10. [Costs of anesthetics and other drugs in anesthesia].
Majstorović BM; Kastratović DA; Milaković BD; Marković SZ; Mijajlović MS; Vucović DS
Med Pregl; 2012; 65(1-2):30-4. PubMed ID: 22452236
[TBL] [Abstract][Full Text] [Related]
11. Knowledge and barriers to early detection of breast cancer among female primary care patients in Serbia.
Šantrić Milićević M; Djurin A; Terzić-Šupić Z; Todorović J; Nikolić D; Soldatović I
Cent Eur J Public Health; 2022 Jun; 30(2):119-130. PubMed ID: 35876601
[TBL] [Abstract][Full Text] [Related]
12. End-of-life costs of medical care for advanced stage cancer patients.
Kovacević A; Dragojević-Simić V; Rancić N; Jurisević M; Gutzwiller FS; Matter-Walstra K; Jakovljević M
Vojnosanit Pregl; 2015 Apr; 72(4):334-41. PubMed ID: 26040179
[TBL] [Abstract][Full Text] [Related]
13. Development of a method to determine the cost of breast cancer treatment with chemotherapy at Groote Schuur Hospital, Cape Town, South Africa.
Guzha NT; Thebe T; Butler N; Valodia PN
S Afr Med J; 2020 Mar; 110(4):296-301. PubMed ID: 32657741
[TBL] [Abstract][Full Text] [Related]
14. Joinpoint regression analysis of female breast cancer mortality in Serbia 1991-2010.
Ilic M; Vlajinac H; Marinkovic J; Vasiljevic S
Women Health; 2013; 53(5):439-50. PubMed ID: 23879456
[TBL] [Abstract][Full Text] [Related]
15. Descriptive epidemiology of breast cancer in Vojvodina.
Stankov S; Stankov K
Breast; 2011 Apr; 20(2):192-5. PubMed ID: 21185723
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing time to seeking medical advice and onset of treatment in women who are diagnosed with breast cancer in Serbia.
Stamatovic L; Vasovic S; Trifunovic J; Boskov N; Gajic Z; Parezanovic A; Icevic M; Cirkovic A; Milic N
Psychooncology; 2018 Feb; 27(2):576-582. PubMed ID: 28857314
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacoeconomic aspects of breast cancer management].
Kolbin AS; Zagorodnikova KA
Vopr Onkol; 2011; 57(5):604-8. PubMed ID: 22238930
[No Abstract] [Full Text] [Related]
18. [Assessment of required resources for implementation of national breast cancer screening program in Serbia].
Majstorović N; Simić S; Matejić B; Cudanov M
Srp Arh Celok Lek; 2014; 142(1-2):59-66. PubMed ID: 24684033
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on the Costs of Cancer Care: A Survey of the American Society of Breast Surgeons.
Greenup RA; Rushing CN; Fish LJ; Lane WO; Peppercorn JM; Bellavance E; Tolnitch L; Hyslop T; Myers ER; Zafar SY; Hwang ES
Ann Surg Oncol; 2019 Oct; 26(10):3141-3151. PubMed ID: 31342390
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation.
Bocci G; Tuccori M; Emmenegger U; Liguori V; Falcone A; Kerbel RS; Del Tacca M
Ann Oncol; 2005 Aug; 16(8):1243-52. PubMed ID: 15905308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
